{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:21:30Z","timestamp":1788776490920,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","exphem.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.exphem.2024.104651","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T02:47:00Z","timestamp":1727837220000},"page":"104651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cellular uptake of CPX-351 by scavenger receptor class B type 1\u2013mediated nonendocytic pathway"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1162-9010","authenticated-orcid":false,"given":"Hiroaki","family":"Araie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-3250","authenticated-orcid":false,"given":"Naoko","family":"Hosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2024.104651_bib0001","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2024.104651_bib0002","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.addr.2011.02.001","article-title":"Physical and chemical stability of drug nanoparticles","volume":"63","author":"Wu","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.exphem.2024.104651_bib0003","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s13346-016-0283-1","article-title":"Improved delivery of poorly soluble compounds using nanoparticle technology: a review","volume":"6","author":"Kalepu","year":"2016","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.exphem.2024.104651_bib0004","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1126\/science.8128245","article-title":"Biodegradable long-circulating polymeric nanospheres","volume":"263","author":"Gref","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.exphem.2024.104651_bib0005","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2024.104651_bib0006","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.01.002","article-title":"Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity","volume":"91","author":"Maeda","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.exphem.2024.104651_bib0007","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.exphem.2024.104651_bib0008","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2024.104651_bib0009","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.exphem.2024.104651_bib0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41565-021-00858-8","article-title":"Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics","volume":"16","author":"Rennick","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.exphem.2024.104651_bib0011","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1039\/D0CS01127D","article-title":"Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine","volume":"50","author":"Sousa de Almeida","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.exphem.2024.104651_bib0012","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1039\/D1CS00707F","article-title":"How can we use the endocytosis pathways to design nanoparticle drug-delivery vehicles to target cancer cells over healthy cells?","volume":"51","author":"Cong","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.exphem.2024.104651_bib0013","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cell.2004.08.017","article-title":"Endocytosis by random initiation and stabilization of clathrin-coated pits","volume":"118","author":"Ehrlich","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2024.104651_bib0014","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrm.2017.132","article-title":"Mechanisms of clathrin-mediated endocytosis","volume":"19","author":"Kaksonen","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.exphem.2024.104651_bib0015","doi-asserted-by":"crossref","first-page":"e24438","DOI":"10.1371\/journal.pone.0024438","article-title":"Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines","volume":"6","author":"dos Santos","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2024.104651_bib0016","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3762\/bjnano.5.174","article-title":"Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages","volume":"5","author":"Kuhn","year":"2014","journal-title":"Beilstein J Nanotechnol"},{"key":"10.1016\/j.exphem.2024.104651_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.100993","article-title":"Revealing macropinocytosis using nanoparticles","volume":"83","author":"Means","year":"2022","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.exphem.2024.104651_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101657","article-title":"A decade of the liposome-protein corona: lessons learned and future breakthroughs in theranostics","volume":"47","author":"Quagliarini","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.exphem.2024.104651_bib0019","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nnano.2013.181","article-title":"Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology","volume":"8","author":"Tenzer","year":"2013","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.exphem.2024.104651_bib0020","doi-asserted-by":"crossref","first-page":"13171","DOI":"10.1021\/am404171h","article-title":"Selective targeting capability acquired with a protein corona adsorbed on the surface of 1,2-dioleoyl-3-trimethylammonium propane\/DNA nanoparticles","volume":"5","author":"Caracciolo","year":"2013","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.exphem.2024.104651_bib0021","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.2217\/nnm-2016-0233","article-title":"Differential uptake of nanoparticles by human M1 and M2 polarized macrophages: protein corona as a critical determinant","volume":"11","author":"Binnemars-Postma","year":"2016","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.exphem.2024.104651_bib0022","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.exphem.2024.104651_bib0023","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.leukres.2012.07.006","article-title":"Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia","volume":"36","author":"Feldman","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2024.104651_bib0024","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2024.104651_bib0025","first-page":"172","article-title":"Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells","volume":"61","author":"Takemura","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2024.104651_bib0026","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bbamem.2015.11.012","article-title":"The protein corona of circulating PEGylated liposomes","volume":"1858","author":"Palchetti","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.exphem.2024.104651_bib0027","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1074\/mcp.M500230-MCP200","article-title":"Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition","volume":"5","author":"Silva","year":"2006","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.exphem.2024.104651_bib0028","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/sj.leu.2401576","article-title":"Relationship between the intracellular daunorubicin concentration, expression of major vault protein\/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia","volume":"13","author":"Den Boer","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2024.104651_bib0029","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/03639045.2018.1513026","article-title":"Scavenger receptor class BI (SR-BI) mediates uptake of CPX-351 into K562 leukemia cells","volume":"45","author":"Di","year":"2019","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.exphem.2024.104651_bib0030","first-page":"1727","article-title":"Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells","volume":"4","author":"van der Kolk","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2024.104651_bib0031","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ejmech.2017.01.019","article-title":"N-alkanol-N-cyclohexanol amine aryl esters: multidrug resistance (MDR) reversing agents with high potency and efficacy","volume":"127","author":"Teodori","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.exphem.2024.104651_bib0032","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.bbamem.2017.09.005","article-title":"Involvement of scavenger receptor class B type 1 and low-density lipoprotein receptor in the internalization of liposomes into HepG2 cells","volume":"1859","author":"Sakai-Kato","year":"2017","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"10.1016\/j.exphem.2024.104651_bib0033","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1111\/bph.14429","article-title":"Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration-approved drugs","volume":"175","author":"Lin","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.exphem.2024.104651_bib0034","doi-asserted-by":"crossref","first-page":"15422","DOI":"10.1073\/pnas.222421399","article-title":"Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI","volume":"99","author":"Nieland","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2024.104651_bib0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbalip.2005.02.007","article-title":"Endocytosis is not required for the selective lipid uptake mediated by murine SR-BI","volume":"1734","author":"Nieland","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.exphem.2024.104651_bib0036","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/bi701277x","article-title":"Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity","volume":"47","author":"Nieland","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.exphem.2024.104651_bib0037","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/cas.12965","article-title":"Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells","volume":"107","author":"Matsuda","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.exphem.2024.104651_bib0038","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/01.ATV.20.4.1074","article-title":"Apolipoprotein AII enrichment of HDL enhances their affinity for class B type I scavenger receptor but inhibits specific cholesteryl ester uptake","volume":"20","author":"Pilon","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.exphem.2024.104651_bib0039","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1194\/jlr.R083121","article-title":"Scavenger receptor B type 1: expression, molecular regulation, and cholesterol transport function","volume":"59","author":"Shen","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.exphem.2024.104651_bib0040","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fendo.2020.00474","article-title":"The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans","volume":"11","author":"Bor\u00e9n","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.exphem.2024.104651_bib0041","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104651_bib0042","doi-asserted-by":"crossref","first-page":"13958","DOI":"10.1039\/C5NR03701H","article-title":"The biomolecular corona of nanoparticles in circulating biological media","volume":"7","author":"Pozzi","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.exphem.2024.104651_bib0043","doi-asserted-by":"crossref","first-page":"17254","DOI":"10.1039\/C7NR06437C","article-title":"An apolipoprotein-enriched biomolecular corona switches the cellular uptake mechanism and trafficking pathway of lipid nanoparticles","volume":"9","author":"Digiacomo","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.exphem.2024.104651_bib0044","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.actbio.2021.07.074","article-title":"Spotlight on the protein corona of liposomes","volume":"134","author":"Onishchenko","year":"2021","journal-title":"Acta Biomater"},{"key":"10.1016\/j.exphem.2024.104651_bib0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/bs.acr.2015.04.004","article-title":"Scavenger receptors: emerging roles in cancer biology and immunology","volume":"128","author":"Yu","year":"2015","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.exphem.2024.104651_bib0046","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-physiol-021317-121550","article-title":"SR-B1: A unique multifunctional receptor for cholesterol influx and efflux","volume":"80","author":"Shen","year":"2018","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.exphem.2024.104651_bib0047","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fphar.2016.00338","article-title":"SR-BI: linking cholesterol and lipoprotein metabolism with breast and prostate cancer","volume":"7","author":"Gutierrez-Pajares","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.exphem.2024.104651_bib0048","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.prp.2016.03.011","article-title":"Up-regulated expression of scavenger receptor class B type 1 (SR-B1) is associated with malignant behaviors and poor prognosis of breast cancer","volume":"212","author":"Li","year":"2016","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.exphem.2024.104651_bib0049","doi-asserted-by":"crossref","first-page":"e0203","DOI":"10.1097\/MD.0000000000010203","article-title":"High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in lung adenocarcinoma: a STROBE compliant article","volume":"97","author":"Feng","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.exphem.2024.104651_bib0050","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317699110","article-title":"Diagnostic and prognostic value of scavenger receptor class B type 1 in clear cell renal cell carcinoma","volume":"39","author":"Xu","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.exphem.2024.104651_bib0051","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.bbrc.2017.10.154","article-title":"Scavenger receptor class B type 1 regulates neuroblastoma cell proliferation, migration and invasion","volume":"495","author":"Panchoo","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2024.104651_bib0052","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1021\/ar200017e","article-title":"Lipoprotein-inspired nanoparticles for cancer theranostics","volume":"44","author":"Ng","year":"2011","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.exphem.2024.104651_bib0053","doi-asserted-by":"crossref","first-page":"7214","DOI":"10.1016\/j.biomaterials.2014.05.009","article-title":"Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis","volume":"35","author":"Ding","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.exphem.2024.104651_bib0054","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1073\/pnas.1213657110","article-title":"Biomimetic, synthetic HDL nanostructures for lymphoma","volume":"110","author":"Yang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2024.104651_bib0055","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1083\/jcb.131.1.69","article-title":"Clathrin-independent pinocytosis is induced in cells overexpressing a temperature-sensitive mutant of dynamin","volume":"131","author":"Damke","year":"1995","journal-title":"J Cell Biol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X24005162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X24005162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T11:51:31Z","timestamp":1733226691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X24005162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":55,"alternative-id":["S0301472X24005162"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2024.104651","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular uptake of CPX-351 by scavenger receptor class B type 1\u2013mediated nonendocytic pathway","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2024.104651","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Experimental Hematology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104651"}}